Pub Date : 2023-07-02DOI: 10.21516/2072-0076-2023-16-2-153-159
G. Arzhimatova, E. A. Salikhov, M. Y. Shemyakin
This review provides a detailed summary of the issues of etiology, pathogenesis and molecular mechanisms of corneal neovascularization. Signaling molecules involved in the process of neovasculogenesis, as well as their antagonists, antiangiogenic factors, are described. The role of signaling proteins VEGF, MMP and their receptors as modern targets of therapy is described on the basis of a series of clinical studies. The potentials of gene and bioengineering therapy as a promising method of treating corneal neovascularization are presented.
{"title":"Corneal neovascularization: a modern view of molecular mechanisms and methods of therapy","authors":"G. Arzhimatova, E. A. Salikhov, M. Y. Shemyakin","doi":"10.21516/2072-0076-2023-16-2-153-159","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-153-159","url":null,"abstract":"This review provides a detailed summary of the issues of etiology, pathogenesis and molecular mechanisms of corneal neovascularization. Signaling molecules involved in the process of neovasculogenesis, as well as their antagonists, antiangiogenic factors, are described. The role of signaling proteins VEGF, MMP and their receptors as modern targets of therapy is described on the basis of a series of clinical studies. The potentials of gene and bioengineering therapy as a promising method of treating corneal neovascularization are presented.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43550398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-02DOI: 10.21516/2072-0076-2023-16-2-183-187
R. Fayzrakhmanov, O. Pavlovsky, G. Karpov
The literature review focuses on penetrating macular holes, a topical issue in vitreoretinal surgery. Multiple theories and the modern view on the pathogenetic mechanisms macular hole formation are presented. A classification of macular holes is proposed.
{"title":"Pathogenetic mechanisms of macular holes: a review of recent research work","authors":"R. Fayzrakhmanov, O. Pavlovsky, G. Karpov","doi":"10.21516/2072-0076-2023-16-2-183-187","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-183-187","url":null,"abstract":"The literature review focuses on penetrating macular holes, a topical issue in vitreoretinal surgery. Multiple theories and the modern view on the pathogenetic mechanisms macular hole formation are presented. A classification of macular holes is proposed.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43964730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-02DOI: 10.21516/2072-0076-2023-16-2-160-165
M. Zueva, N. V. Neroeva, L. Katargina, A. Zhuravleva, V. Kotelin, I. Tsapenko, D. V. Fadeev
Retinal structural plasticity is manifested in multiple damages of the retina. In many cases, the response to these damages is identical at both the cellular and molecular levels, involves similar sets of cellular signals, and is associated with a change in the structure of the retina and remodeling of the neural connections. The review discusses the common and specific features of adaptive and non-adaptive retinal plasticity, which characterize glaucoma, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and retinopathy of prematurity. Given the common features of neurodegeneration and retinal plasticity in brain and retinal diseases, similar therapeutic strategies can be used in many cases to preserve the structure connectivity and retinal function, which stop or slow down the clinical evolution of the disease by either suppressing primary events or enhancing compensatory and regenerative mechanisms in the nervous tissue. Part 2 of the review will present neuroplasticity-based modifying therapy methods for retinal degenerative diseases.
{"title":"Modifying treatment of degenerative retinal diseases. Part 1. Adaptive and non-adaptive retinal plasticity","authors":"M. Zueva, N. V. Neroeva, L. Katargina, A. Zhuravleva, V. Kotelin, I. Tsapenko, D. V. Fadeev","doi":"10.21516/2072-0076-2023-16-2-160-165","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-160-165","url":null,"abstract":"Retinal structural plasticity is manifested in multiple damages of the retina. In many cases, the response to these damages is identical at both the cellular and molecular levels, involves similar sets of cellular signals, and is associated with a change in the structure of the retina and remodeling of the neural connections. The review discusses the common and specific features of adaptive and non-adaptive retinal plasticity, which characterize glaucoma, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and retinopathy of prematurity. Given the common features of neurodegeneration and retinal plasticity in brain and retinal diseases, similar therapeutic strategies can be used in many cases to preserve the structure connectivity and retinal function, which stop or slow down the clinical evolution of the disease by either suppressing primary events or enhancing compensatory and regenerative mechanisms in the nervous tissue. Part 2 of the review will present neuroplasticity-based modifying therapy methods for retinal degenerative diseases.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45848378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-02DOI: 10.21516/2072-0076-2023-16-2-166-172
S. Zyryanov, O. Butranova
The symptoms of most pathological conditions in ophthalmology are based on inflammations of varying severity. Valuable tools against inflammation are topical glucocorticoids (tGCs), whose molecules are able to actively overcome biological membranes and ensure a rapid clinical response. The use of tGCs is accompanied by a wide range of effects, including side effects, a rise in intraocular pressure being one of the most significant ones. The review focuses on a comparative analysis of the efficacy and safety of various tGCs, including “soft steroids”. We show the relationship between the structure of the drugs, their pharmacodynamic effects and the possibility of being used in various eye diseases.
{"title":"Topical glucocorticoids in ophthalmology: a comparative analysis of efficacy and safety","authors":"S. Zyryanov, O. Butranova","doi":"10.21516/2072-0076-2023-16-2-166-172","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-166-172","url":null,"abstract":"The symptoms of most pathological conditions in ophthalmology are based on inflammations of varying severity. Valuable tools against inflammation are topical glucocorticoids (tGCs), whose molecules are able to actively overcome biological membranes and ensure a rapid clinical response. The use of tGCs is accompanied by a wide range of effects, including side effects, a rise in intraocular pressure being one of the most significant ones. The review focuses on a comparative analysis of the efficacy and safety of various tGCs, including “soft steroids”. We show the relationship between the structure of the drugs, their pharmacodynamic effects and the possibility of being used in various eye diseases.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41551669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-02DOI: 10.21516/2072-0076-2023-16-2-140-145
A. V. Pleskova, I. R. Mamakaeva, L. Katargina, A. Panova, K. V. Lugovkina
Preliminary data show that the incidence of eye damage in COVID-19 reaches 32%, with a diverse range of clinical manifestations. Both the anterior segment of the eye (conjunctivitis, keratoconjunctivitis) and the posterior segment (retinal vascular thrombosis, neuritis, neuroretinitis) can be affected. The infection in children is diagnosed much less frequently than in adults, so ophthalmic manifestations have hardly ever been studied.Purpose: to present cases of congenital eye lesions in children born to mothers who had COVID-19 during pregnancy.Material. We present 4 clinical cases of ocular manifestations in newborns born to such mothers.Results. 4 variants of congenital ocular manifestations are reported. Clinical manifestations are listed, and treatment tactics for such patients is proposed.Conclusion. In order to timely diagnose, and choose the optimal treatment tactics of such conditions, thorough collection of case history and the ophthalmologists’ awareness of ocular symptoms of COVID-19 manifestations is essential.
{"title":"Congenital ocular manifestations in children born to mothers who had COVID-19 coronavirus infection during pregnancy. Clinical cases","authors":"A. V. Pleskova, I. R. Mamakaeva, L. Katargina, A. Panova, K. V. Lugovkina","doi":"10.21516/2072-0076-2023-16-2-140-145","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-140-145","url":null,"abstract":"Preliminary data show that the incidence of eye damage in COVID-19 reaches 32%, with a diverse range of clinical manifestations. Both the anterior segment of the eye (conjunctivitis, keratoconjunctivitis) and the posterior segment (retinal vascular thrombosis, neuritis, neuroretinitis) can be affected. The infection in children is diagnosed much less frequently than in adults, so ophthalmic manifestations have hardly ever been studied.Purpose: to present cases of congenital eye lesions in children born to mothers who had COVID-19 during pregnancy.Material. We present 4 clinical cases of ocular manifestations in newborns born to such mothers.Results. 4 variants of congenital ocular manifestations are reported. Clinical manifestations are listed, and treatment tactics for such patients is proposed.Conclusion. In order to timely diagnose, and choose the optimal treatment tactics of such conditions, thorough collection of case history and the ophthalmologists’ awareness of ocular symptoms of COVID-19 manifestations is essential.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44053537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-02DOI: 10.21516/2072-0076-2023-16-2-173-176
E. E. Ioileva, A. Safonenko, O. V. Golubeva, K. Bolbachan
The review summarizes the evidence of visual and neurological complications in the acute stage of COVID-19 and in post-COVID syndrome. Neurological symptom complexes, and cerebrovascular disorders are described. Ophthalmologic manifestations may be a typical sign of COVID-19 onset, but they may also develop several weeks after recovery. The spectrum of neuro-ophthalmological manifestations in most cases includes optic neuritis, optic disc edema, optic neuropathy, and venous thrombosis. Ophthalmologists should be aware of the possible associations of ocular diseases with COVID-19 in order to diagnose and initiate an early treatment for life and vision threatening complications.
{"title":"Visual and neurological complications of COVID-19","authors":"E. E. Ioileva, A. Safonenko, O. V. Golubeva, K. Bolbachan","doi":"10.21516/2072-0076-2023-16-2-173-176","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-173-176","url":null,"abstract":"The review summarizes the evidence of visual and neurological complications in the acute stage of COVID-19 and in post-COVID syndrome. Neurological symptom complexes, and cerebrovascular disorders are described. Ophthalmologic manifestations may be a typical sign of COVID-19 onset, but they may also develop several weeks after recovery. The spectrum of neuro-ophthalmological manifestations in most cases includes optic neuritis, optic disc edema, optic neuropathy, and venous thrombosis. Ophthalmologists should be aware of the possible associations of ocular diseases with COVID-19 in order to diagnose and initiate an early treatment for life and vision threatening complications.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48300484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.21516/2072-0076-2023-16-2-130-134
A. Babushkin, E. N. Matyukhina, G. R. Saitova, G. Israfilova
A clinical case of viral conjunctivitis COVID-19, which was complicated by partial symblepharon and severe dry eye syndrome, is presented. The latter was treated for several days with eye drops containing solutions of glucocorticosteroid, a cytostatic and an antiseptic combined with tear replacement therapy, which however led to an extensive detachment of the corneal epithelium of the right eye, a superficial ulcer and an area of keratomalacia in the lower part of the cornea. In view of this, a further hospital treatment was required: the patient received anti-inflammatory and keratoprotective drugs. A subsequent medical consultation found out that the patient had periodically instilled oxybuprocaine hydrochloride 0.4% into the right eye for pain relief for a long time (4 months) without informing the attending physician. As a result of hospital treatment, the condition of the patient’s right eye improved: the corneal ulcer, was epithelialized, followed by the formation of a vascularized corneal leukoma. In our opinion, a deterioration of the tear film stability of the patient, who had had COVID-19 accompanied by ocular manifestations in the form of initially developed conjunctivitis, was due to the anesthetic effect of long-term instillations of oxybuprocaine hydrochloride. This led to a significant decrease in tear secretion, a decrease in the density of goblet cells of the conjunctiva and a violation of the sensory innervation of the cornea, which gradually brought about a severe dry eye syndrome. The above case clearly demonstrates the importance of increasing the patients’ awareness of the harm that could be caused by long-term use of local anesthetics without a doctor’s approval.
{"title":"Complicated COVID-19 conjunctivitis. A case report","authors":"A. Babushkin, E. N. Matyukhina, G. R. Saitova, G. Israfilova","doi":"10.21516/2072-0076-2023-16-2-130-134","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-130-134","url":null,"abstract":"A clinical case of viral conjunctivitis COVID-19, which was complicated by partial symblepharon and severe dry eye syndrome, is presented. The latter was treated for several days with eye drops containing solutions of glucocorticosteroid, a cytostatic and an antiseptic combined with tear replacement therapy, which however led to an extensive detachment of the corneal epithelium of the right eye, a superficial ulcer and an area of keratomalacia in the lower part of the cornea. In view of this, a further hospital treatment was required: the patient received anti-inflammatory and keratoprotective drugs. A subsequent medical consultation found out that the patient had periodically instilled oxybuprocaine hydrochloride 0.4% into the right eye for pain relief for a long time (4 months) without informing the attending physician. As a result of hospital treatment, the condition of the patient’s right eye improved: the corneal ulcer, was epithelialized, followed by the formation of a vascularized corneal leukoma. In our opinion, a deterioration of the tear film stability of the patient, who had had COVID-19 accompanied by ocular manifestations in the form of initially developed conjunctivitis, was due to the anesthetic effect of long-term instillations of oxybuprocaine hydrochloride. This led to a significant decrease in tear secretion, a decrease in the density of goblet cells of the conjunctiva and a violation of the sensory innervation of the cornea, which gradually brought about a severe dry eye syndrome. The above case clearly demonstrates the importance of increasing the patients’ awareness of the harm that could be caused by long-term use of local anesthetics without a doctor’s approval.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49044941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.21516/2072-0076-2023-16-2-83-91
A. Surov, M. Medvedeva, S. F. Sagirova, T. Konstantinova, L. V. Gabatova, O. G. Moroz
Purpose: to assess the effectiveness of the combined interferon alpha-2b-based medicine (Ophtalmoferon, eye drops) in the complex treatment of herpetic keratitis in patients who had coronavirus infection caused by SARS-CoV-2.Materials and methods. The study group included 53 people aged 18 to 74 years (mean age 46.0 ± 7.8 years) with the following complaints: decreased vision, redness, eye pain, lacrimation, photophobia and foreign body sensation under the eyelid. Criteria for selection and inclusion of patients were: typical for herpetic keratitis corneal infiltrates detected by biomicroscopy; herpetic infection detected by Polymerase Chain Reaction (PCR) in the affected eye corneal scrape; a medical history of the novel coronavirus infection confirmed by PCR. The patients were divided into two groups. Group 1 (n = 32) received complex treatment with the combined interferon alpha-2b-based medicine (Ophtalmoferon®, eye drops) at early stages of the disease (from the 1st to 7th day after the first complaints). Group 2 (n = 21) received complex treatment with Ophtalmoferon® at later stages (from the 14th day of the first complaints). The effectiveness and tolerability of Ophtalmoferon were assessed during the dynamic monitoring of the patients.Results. A positive trend was noted in 79.2 % (n = 42) of all patients who received Ophtalmoferon for the complex treatment of herpetic keratitis: a gradual improvement in visual acuity, reduction or disappearance of photophobia, lacrimation and eye pain. In 20.8 % (n = 11) of all cases, mostly related to the late start of etiological therapy, the treatment effectiveness was lower, the disease lasted longer and was accompanied by the involvement of the choroid, the development of more severe opacities in the place of corneal infiltrates. Due to later start of etiotropic therapy the inflammatory process affected deeper layers of the cornea up to the development of corneal ulcer with perforation, which required surgical intervention.Conclusion. The etiotropic treatment of herpetic keratitis in patients after COVID-19, if started in the first days of the disease, can quickly stop the inflammatory process and prevent its spread to deeper layers of the cornea. Ophtalmoferon is a highly effective medicine for etiotropic treatment of keratitis caused by herpesviruses. Due to high patient compliance, Ophtalmoferon can be recommended for wide use in the complex therapy of herpetic keratitis.
{"title":"The use of combined interferon alpha-2b-based medicine in the complex treatment of herpetic keratitis in patients after coronavirus infection","authors":"A. Surov, M. Medvedeva, S. F. Sagirova, T. Konstantinova, L. V. Gabatova, O. G. Moroz","doi":"10.21516/2072-0076-2023-16-2-83-91","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-83-91","url":null,"abstract":"Purpose: to assess the effectiveness of the combined interferon alpha-2b-based medicine (Ophtalmoferon, eye drops) in the complex treatment of herpetic keratitis in patients who had coronavirus infection caused by SARS-CoV-2.Materials and methods. The study group included 53 people aged 18 to 74 years (mean age 46.0 ± 7.8 years) with the following complaints: decreased vision, redness, eye pain, lacrimation, photophobia and foreign body sensation under the eyelid. Criteria for selection and inclusion of patients were: typical for herpetic keratitis corneal infiltrates detected by biomicroscopy; herpetic infection detected by Polymerase Chain Reaction (PCR) in the affected eye corneal scrape; a medical history of the novel coronavirus infection confirmed by PCR. The patients were divided into two groups. Group 1 (n = 32) received complex treatment with the combined interferon alpha-2b-based medicine (Ophtalmoferon®, eye drops) at early stages of the disease (from the 1st to 7th day after the first complaints). Group 2 (n = 21) received complex treatment with Ophtalmoferon® at later stages (from the 14th day of the first complaints). The effectiveness and tolerability of Ophtalmoferon were assessed during the dynamic monitoring of the patients.Results. A positive trend was noted in 79.2 % (n = 42) of all patients who received Ophtalmoferon for the complex treatment of herpetic keratitis: a gradual improvement in visual acuity, reduction or disappearance of photophobia, lacrimation and eye pain. In 20.8 % (n = 11) of all cases, mostly related to the late start of etiological therapy, the treatment effectiveness was lower, the disease lasted longer and was accompanied by the involvement of the choroid, the development of more severe opacities in the place of corneal infiltrates. Due to later start of etiotropic therapy the inflammatory process affected deeper layers of the cornea up to the development of corneal ulcer with perforation, which required surgical intervention.Conclusion. The etiotropic treatment of herpetic keratitis in patients after COVID-19, if started in the first days of the disease, can quickly stop the inflammatory process and prevent its spread to deeper layers of the cornea. Ophtalmoferon is a highly effective medicine for etiotropic treatment of keratitis caused by herpesviruses. Due to high patient compliance, Ophtalmoferon can be recommended for wide use in the complex therapy of herpetic keratitis.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67950141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.21516/2072-0076-2023-16-2-99-107
E. Eskina, A. Belogurova, A. A. Gvetadze, A. S. Smorchkova
The effectiveness of nutraceutical drug containing oxycarotenoids, vitamins and trace elements, aimed at inhibiting the progression of the dry form of age-related macular degeneration (AMD) has been demonstrated in clinical studies.The purpose of this research is to evaluate the effectiveness of long-term use of a nutraceutical drug in reducing the risk of intermediate AMD evolving into wet AMD, and assess whether it is worth using in patients with wet AMD to reduce the average yearly number of intravitreal injections of angiogenesis inhibitors.Materials and methods. In the first part of the study, we monitored 46 patients with intermediate AMD threatening the progression of the disease (those with multiple confluent drusen, drusenoid, pigment epithelium detachment) for a year: some of them received the drug while others had no nutraceutical support. We assessed standard visual functions, as well as reading parameters (on the Salzburg Reading Desk device), spatial frequency contrast sensitivity (SFC) according to the Zebra program, and macular pigment optical density (on the MPOD device). Retina parameters were controlled by photofixation using Kowa and Clarus 500 fundus camera, and by optical coherence tomography with angiography using a Cirrus 5000 Angioplex, Carl Zeiss. The disease was considered to be progressing if signs of neovascular AMD were detected. In the second part of the study, 35 patients with newly diagnosed neovascular AMD were followed up for a year and treated with angiogenesis inhibitors according to the following pattern: three loading injections of aflibercept and then pro re nata. Of two groups of patients with signs of neovascular AMD, one group took a nutraceutical drug (Lutrin, S.C. Rompharm Company S.R.L., Romania). The number of intravitreal injections of aflibercept administered according to indications during the year was estimated.Results. In the first part of the study, patients with intermediate AMD taking the drug showed an increase in MPOD from 0.36 ± 0.11 to 0.45 ± 0.15 (p = 0.05) and a stable state of the retina and visual functions throughout the entire observation period. In 2 patients (12.5 %) who did not take the drug, the disease progressed to a neovascular form. In the second part of the study, the patients taking the drug received an average of 3.4 ± 0.7 intravitreal injections of aflibercept during the year, compared with 5.3 ± 1.2 injections in the control group without nutraceutical support.Conclusion. Nutraceutical drugs are effective in reducing the risk of intermediate AMD evolving into wet AMD, and thus advisable for patients with wet AMD to reduce the average yearly number of intravitreal injections of angiogenesis inhibitors.
{"title":"Åfficacy of nutraceutical drug in the intermediate and wet forms of age-related macular degeneration","authors":"E. Eskina, A. Belogurova, A. A. Gvetadze, A. S. Smorchkova","doi":"10.21516/2072-0076-2023-16-2-99-107","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-99-107","url":null,"abstract":"The effectiveness of nutraceutical drug containing oxycarotenoids, vitamins and trace elements, aimed at inhibiting the progression of the dry form of age-related macular degeneration (AMD) has been demonstrated in clinical studies.The purpose of this research is to evaluate the effectiveness of long-term use of a nutraceutical drug in reducing the risk of intermediate AMD evolving into wet AMD, and assess whether it is worth using in patients with wet AMD to reduce the average yearly number of intravitreal injections of angiogenesis inhibitors.Materials and methods. In the first part of the study, we monitored 46 patients with intermediate AMD threatening the progression of the disease (those with multiple confluent drusen, drusenoid, pigment epithelium detachment) for a year: some of them received the drug while others had no nutraceutical support. We assessed standard visual functions, as well as reading parameters (on the Salzburg Reading Desk device), spatial frequency contrast sensitivity (SFC) according to the Zebra program, and macular pigment optical density (on the MPOD device). Retina parameters were controlled by photofixation using Kowa and Clarus 500 fundus camera, and by optical coherence tomography with angiography using a Cirrus 5000 Angioplex, Carl Zeiss. The disease was considered to be progressing if signs of neovascular AMD were detected. In the second part of the study, 35 patients with newly diagnosed neovascular AMD were followed up for a year and treated with angiogenesis inhibitors according to the following pattern: three loading injections of aflibercept and then pro re nata. Of two groups of patients with signs of neovascular AMD, one group took a nutraceutical drug (Lutrin, S.C. Rompharm Company S.R.L., Romania). The number of intravitreal injections of aflibercept administered according to indications during the year was estimated.Results. In the first part of the study, patients with intermediate AMD taking the drug showed an increase in MPOD from 0.36 ± 0.11 to 0.45 ± 0.15 (p = 0.05) and a stable state of the retina and visual functions throughout the entire observation period. In 2 patients (12.5 %) who did not take the drug, the disease progressed to a neovascular form. In the second part of the study, the patients taking the drug received an average of 3.4 ± 0.7 intravitreal injections of aflibercept during the year, compared with 5.3 ± 1.2 injections in the control group without nutraceutical support.Conclusion. Nutraceutical drugs are effective in reducing the risk of intermediate AMD evolving into wet AMD, and thus advisable for patients with wet AMD to reduce the average yearly number of intravitreal injections of angiogenesis inhibitors.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46858949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.21516/2072-0076-2023-16-2-108-112
E. V. Yani, K. E. Seliverstova
Purpose: to evaluate the effectiveness of corneal collagen crosslinking (CCC) with a portable Keratolink device in patients with bullous keratopathy after cataract surgery.Materials and methods. 19 patients (19 eyes) aged 60 to 87 with secondary epithelial-endothelial corneal dystrophy, developed due to cataract surgery received three CCC procedures which lasted 20 minutes each, with intervals of 2 days between the procedures.Results. The mean corneal pain score according to verbal pain scale decreased to 4.5 from the initial 9 points and did not change significantly at subsequent visits. Optical coherence tomography data show that before the first procedure, the average corneal transparency score was 2.8 while by the 20th day of observation it fell to 1.4 points. After 3 CCC procedures, bullae continued to form in 3 patients only (3 eyes, 16 %) over the entire 3-month-long observation period. The best corrected visual acuity 3 months after CСC in patients was about 0.07 ± 0.02, which is slightly higher than the initial value (0.05 ± 0.03).Conclusion. A short course of ultraviolet CCC with a portable Keratolink device may be recommended as a palliative treatment for elderly patients with bullous keratopathy developed after cataract surgery.
{"title":"Therapeutic possibilities for secondary epithelial-endothelial corneal dystrophy using a portable device for local collagen crosslinking","authors":"E. V. Yani, K. E. Seliverstova","doi":"10.21516/2072-0076-2023-16-2-108-112","DOIUrl":"https://doi.org/10.21516/2072-0076-2023-16-2-108-112","url":null,"abstract":"Purpose: to evaluate the effectiveness of corneal collagen crosslinking (CCC) with a portable Keratolink device in patients with bullous keratopathy after cataract surgery.Materials and methods. 19 patients (19 eyes) aged 60 to 87 with secondary epithelial-endothelial corneal dystrophy, developed due to cataract surgery received three CCC procedures which lasted 20 minutes each, with intervals of 2 days between the procedures.Results. The mean corneal pain score according to verbal pain scale decreased to 4.5 from the initial 9 points and did not change significantly at subsequent visits. Optical coherence tomography data show that before the first procedure, the average corneal transparency score was 2.8 while by the 20th day of observation it fell to 1.4 points. After 3 CCC procedures, bullae continued to form in 3 patients only (3 eyes, 16 %) over the entire 3-month-long observation period. The best corrected visual acuity 3 months after CСC in patients was about 0.07 ± 0.02, which is slightly higher than the initial value (0.05 ± 0.03).Conclusion. A short course of ultraviolet CCC with a portable Keratolink device may be recommended as a palliative treatment for elderly patients with bullous keratopathy developed after cataract surgery.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44002133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：